SCSarah J. Chapple

Sarah J. Chapple

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah J. Chapple has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanni Enrico Mann

    King's British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, 150 Stamford Street, London, SE1 9NH, UK

    9 shared publications
  • Giovanni E. Mann

    King's British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom

    6 shared publications
  • Paul D. Taylor

    Department of Women and Children’s Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK

    4 shared publications
  • Richard C.M. Siow

    Cardiovascular Division, British Heart Foundation Centre of Research Excellence, Faculty of Life Sciences & Medicine, King's College London, 150 Stamford Street, London SE1 9NH, UK

    4 shared publications
  • Jessica Morris

    King's College London, London, United Kingdom

    3 shared publications
  • Paraskevi-Maria Psefteli

    School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK

    3 shared publications

Latest Publications

  • Open Access

    Sulforaphane induced NRF2 activation in obese pregnancy attenuates developmental redox imbalance and improves early-life cardiovascular function in offspring

    by Paraskevi-Maria Psefteli, Jessica K. Morris, Elisabeth Ehler, Lorna Smith, James Bowe, Giovanni E. Mann, Paul D. Taylor, Sarah J. Chapple


  • At the heart of the matter: Nrf2 modulates offspring cardiovascular phenotype following obese/GDM pregnancy

    by Paraskevi-Maria Psefteli, Jessica K. Morris, Paul D. Taylor, Elisabeth Ehler, Luigi Gnudi, Giovanni E. Mann, Sarah J. Chapple

  • Nrf2 activator Sulforaphane improves maternal glucose tolerance and vascular function in obese pregnancy

    by Jessica Morris, Paraskevi, Maria Psefteli, Luigi Gnudi, James Bowe, Paul Taylor, Manasi Nandi, Sarah Chapple

  • Effect of sulforaphane, an activator of the Nrf2 antioxidant defence pathway, on maternal adiposity in a model of diet-induced insulin resistant pregnancy

    by Alokya Balagamage, Paraskevi-Maria Psefteli, Jessica Morris, Paul Taylor, Giovanni Mann, Sarah Chapple

    The incidence of maternal obese and/or gestational diabetic (GDM) pregnancy are increasing globally, with ~10-20% of mothers classified as obese and/or GDM within the U.K. Both obese and GDM pregnancy are associated with increased risk of cardiometabolic disease, with mothers and their children at greater risk of developing later-life Type 2 diabetes, obesity and/or cardiovascular disease. Higher adiposity in pregnancy leads to increased inflammation, which may be countered by antioxidant defence genes regulated by the transcription factor Nrf2. Dietary activators of Nrf2 such as sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables such as broccoli, may therefore be used as anti-obesogenic cardiovascular protectants. In this study we examined the effect of SFN on maternal adiposity. C57BL/6 WT and Nrf2 deficient dams were fed a highly palatable obesogenic diet 6 weeks prior to pregnancy, then received with vehicle (corn oil) or SFN throughout pregnancy and the postpartum period. Inguinal and parametrial fat pads were weighed at termination, tissued fixed with 5µm sections stained with H&E to measure adipocyte area. SFN treatment reduced maternal inguinal and to a lesser extent parametrial adipose depots in WT dams. Nrf2 deficient dams treated with SFN showed no change in adipose fat pad mass. Preliminary data showed parametrial adipocyte area was reduced by SFN treatment in WT not Nrf2 deficient dams, however Nrf2 deficiency by itself resulted in a reduced adipocyte size. In summary, SFN has anti-adipogenic properties and appears to mediate its effects through Nrf2, however Nrf2 deficiency by itself alters adipose morphology.

  • Nrf2 activator Sulforaphane attenuates maternal adiposity and hepatic steatosis

    by Paraskevi-Maria Psefteli, Alokya Balagamage, Jessica Morris, Paul Taylor, Giovanni Mann, Sarah Chapple

    Intro/Aims: Maternal obesity is a major risk factor for the development of first onset of diabetes in pregnancy, also known as gestational diabetes mellitus (GDM). Recent studies also indicate that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of GDM. Sulforaphane (SFN) is a well-known dietary activator of the redox-sensitive transcription factor Nrf2, with reported anti-adipogenic and NAFLD ameliorating effects in non-pregnant obese rodent models. In this study we sought to determine whether sulforaphane could exert metabolic protection in GDM murine dams. Methods: Wildtype (WT) and Nrf2 deficient C57BL/6 dams were fed a highly palatable obesogenic diet 6 weeks prior to pregnancy, then received either vehicle (corn oil) or SFN throughout pregnancy and the postpartum period. Bodyweight was measured throughout the developmental period, with visceral and subcutaneous adiposity (parametrial and inguinal fat pads, respectively measured relative to bodyweight and tibia length) determined upon post-partum termination. H&E staining of liver tissue was used to quantify maternal steatosis. Results: SFN significantly reduced postnatal weight retention, with a reduction in subcutaneous inguinal adipose tissue depots noted in WT not Nrf2 deficient dams. Preliminary results also indicate that hepatic lipid deposition quantified as % lipid area and mean lipid area were also attenuated by SFN intervention in WT not Nrf2 deficient dams. Conclusion: SFN exerts maternal metabolic protection against obesogenic dietary feeding, reducing subcutaneous adipose deposition as well as liver lipid accumulation. Protection is ameliorated in Nrf2 deficient dams suggesting that SFNs protective effects are mediated via Nrf2 activation.

  • Open Access

    The glucose tolerance test in mice: Sex, drugs and protocol

    by Matilda R. Kennard, Manasi Nandi, Sarah Chapple, Aileen J. King

    Aim: To establish the impact of sex, dosing route, fasting duration and acute habituation stress on glucose tolerance test (GTT) measurements used in the preclinical evaluation of potential glucose‐modulating therapeutics. Methods: Adult male and female C57Bl/6J mice, implanted with HD‐XG glucose telemetry devices, were fasted for 16 hours or 6 hours following acute habituation stress due to whole cage change, cage change with retention of used bedding or no cage change prior to intraperitoneal (IP) GTTs. To evaluate protocol refinement and sex on the ability of the GTT to detect drug effects, we administered 250 mg/kg oral metformin or 10 nmol/kg IP exendin‐4 using optimized protocols. Results: Female mice were less sensitive to human intervention when initiating fasting. Following a 6‐hour fast, retention of bedding whilst changing the cage base promotes quicker stabilization of basal blood glucose in both sexes. Prolonged fasting for 16 hours resulted in an exaggerated GTT response but induced pronounced basal hypoglycaemia. Following GTT protocol optimization the effect of exendin‐4 and metformin was equivalent in both sexes, with females showing a more modest but more reproducible GTT response. Conclusions: Variations in GTT protocol have profound effects on glucose homeostasis. Protocol refinement and/or the use of females still allows for detection of drug effects, providing evidence that more severe phenotypes are not an essential prerequisite when characterizing/validating new drugs.


  • Open Access

    Glycocalyx sialic acids regulate Nrf2-mediated signaling by fluid shear stress in human endothelial cells

    by Paraskevi-Maria Psefteli, Phoebe Kitscha, Gema Vizcay, Roland Fleck, Sarah J. Chapple, Giovanni E. Mann, Mark Fowler, Richard C. Siow


  • Messing with metabolism: lessons from an IUGR fetus

    by Sarah J. Chapple, Giovanni E. Mann


  • Open Access

    New Tricks for Nrf2: Therapeutic Targeting to Restore BK-β1 Expression?

    by Sarah J. Chapple, Giovanni E. Mann

    The transcription factor nuclear factor erythroid-2–related factor 2 (Nrf2) is ubiquitously expressed and a master regulator of antioxidant, phase II, and proteostatic genes induced by oxidative or electrophilic stress (1,2). Basally, Nrf2 is continually synthesized and associates with adaptor protein Kelch-like ECH-associated protein 1 (Keap1), resulting in its ubiquitination and rapid degradation via the 26S proteasome (3–5). Following oxidative challenge, modification of essential cysteine residues on Keap1 prevent Nrf2 degradation, allowing de novo Nrf2 to translocate to the nucleus and initiate transcription of target genes containing an antioxidant or electrophilic response element in their promoter region. In cells, failure to activate Nrf2 defenses increases their susceptibility to oxidative damage and dysfunction, contributing to the pathogenesis of various cardiometabolic disease states including hypertension, cardiomyopathy, gestational diabetes mellitus, and type 2 diabetes (6–8). In this issue of Diabetes , Lu et al. (9) demonstrate a novel role for Nrf2 in the regulation of the large conductance Ca2+-activated K+ (BK) channel β1 subunit (BK-β1). As with other recently identified Nrf2-regulated solute transporters, this channel has no intrinsic antioxidant activity but is nevertheless important in homeostatic control of cell function. BK channels are expressed on vascular endothelial cells and smooth muscle cells (SMCs) and consist of a tetramer of α-subunits, containing a channel pore domain, voltage sensor, and Ca2+-sensing region. These α-subunits are each associated with a tissue-specific modulatory β-subunit (isoforms β1–4), altering channel activity (10). The β1-subunit is abundantly expressed in vascular SMCs and enhances the BK channels sensitivity to Ca2+ (11). Activation of BK channels leads to K+ efflux, resulting in membrane hyperpolarization and inhibition of …